Open AccessRole of endoethelin-1 in development of neprhopathy induced with streptozocin
Author(s) -
Jasmina Trojachanec,
Dimče Zafirov,
Maja Slaninka-Miceska,
Nikola Labachevski,
Elena Kostova,
Kalina Georgievska,
Petar Miloschevski,
Stojmir Petrov
Publication year - 2006
Publication title -
makedonsko farmacevtski bilten/makedonski farmacevtski bilten
Language(s) - English
Resource type - Journals
eISSN - 1857-8969
pISSN - 1409-8695
DOI - 10.33320/maced.pharm.bull.2006.52.009
Subject(s) - microalbuminuria , streptozocin , medicine , diabetic nephropathy , enalapril , diabetes mellitus , nephropathy , endocrinology , creatinine , polyuria , urine , urology , blood pressure , streptozotocin , angiotensin converting enzyme
The main aim of our study was to detect changes in plasma level of endoethelin-1 after experimentally induced diabetes and diabetic nephropathy with streptozocin in rats. The effects of ACE inhibitors are well known and thus, we wanted to analyze the influence of enalapril (ACE inhibitor) on plasma concentrations of endoethelin-1 as well as its effects in the treatment of diabetic nephropathy. Single i.p. administration of streptozocin (STZ) caused a significant increase of endoethelin-1 plasma concentrations associated with distinct signs and symptoms of diabetic nephropathy (microalbuminuria, increased urine N-acetyl-D-glucosamidase, increased serum concentrations of urea and creatinine, polyuria). Four-week treatment with endoethelin-1 resulted in significant reduction of endoethelin-1 plasma concentrations and improved sings and symptoms of diabetic nephropathy. The results obtained have confirmed that endoethelin-1 may play an important role in development and progression of diabetic nephropathy and ACE inhibitors, that is enalapril, may alleviate and delay the progression of diabetic nephropathy